Calcium and vitamin d supplementation during androgen deprivation therapy for prostate cancer: A critical review

Mridul Datta, Gary G. Schwartz

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Background.Lossofbonemineraldensityisanunintended consequence of androgen deprivation therapy in men with prostate cancer. Supplementation with calcium and/or vitamin D in these men seems logical and is advocated by many lay and professional groups. Methods. We reviewed guidelines for calcium and vitamin D supplementation and the results of clinical trials of calcium and vitamin D supplementation on bone mineral density in men with prostate cancer undergoing androgen deprivation therapy. Results. Whether supplementation of men undergoing androgen deprivation therapy with calcium and/or vitamin D results in higher bone mineral density than no supplementation has not been tested. The results of 12 clinical trials show that, at the doses commonly recommended, 500-1,000 mg calcium and 200-500 IU vitamin D per day, men undergoing androgen deprivation lose bone mineral density. Conclusion. The doses of calcium and vitamin D that have been tested are inadequate to prevent loss of bone mineral density in men undergoing androgen deprivation therapy. In light of evidence that high levels of dietary calcium and calcium supplement use are associated with higher risks for cardiovascular disease and advanced prostate cancer, intervention studies should evaluate the safety as well as the efficacy of calcium and vitamin D supplementation in these men.

Original languageEnglish (US)
Pages (from-to)1171-1179
Number of pages9
JournalOncologist
Volume17
Issue number9
DOIs
StatePublished - Sep 1 2012

Fingerprint

Vitamins
Androgens
Vitamin D
Prostatic Neoplasms
Calcium
Bone Density
Therapeutics
Clinical Trials
Dietary Calcium
Cardiovascular Diseases
Guidelines
Safety

Keywords

  • Androgen deprivation therapy
  • Bone mineral density
  • Calcium
  • Clinical trials
  • Prostate cancer
  • Vitamin d

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Calcium and vitamin d supplementation during androgen deprivation therapy for prostate cancer : A critical review. / Datta, Mridul; Schwartz, Gary G.

In: Oncologist, Vol. 17, No. 9, 01.09.2012, p. 1171-1179.

Research output: Contribution to journalReview article

@article{3ec732512b9c4e7c96ee250320fa4e73,
title = "Calcium and vitamin d supplementation during androgen deprivation therapy for prostate cancer: A critical review",
abstract = "Background.Lossofbonemineraldensityisanunintended consequence of androgen deprivation therapy in men with prostate cancer. Supplementation with calcium and/or vitamin D in these men seems logical and is advocated by many lay and professional groups. Methods. We reviewed guidelines for calcium and vitamin D supplementation and the results of clinical trials of calcium and vitamin D supplementation on bone mineral density in men with prostate cancer undergoing androgen deprivation therapy. Results. Whether supplementation of men undergoing androgen deprivation therapy with calcium and/or vitamin D results in higher bone mineral density than no supplementation has not been tested. The results of 12 clinical trials show that, at the doses commonly recommended, 500-1,000 mg calcium and 200-500 IU vitamin D per day, men undergoing androgen deprivation lose bone mineral density. Conclusion. The doses of calcium and vitamin D that have been tested are inadequate to prevent loss of bone mineral density in men undergoing androgen deprivation therapy. In light of evidence that high levels of dietary calcium and calcium supplement use are associated with higher risks for cardiovascular disease and advanced prostate cancer, intervention studies should evaluate the safety as well as the efficacy of calcium and vitamin D supplementation in these men.",
keywords = "Androgen deprivation therapy, Bone mineral density, Calcium, Clinical trials, Prostate cancer, Vitamin d",
author = "Mridul Datta and Schwartz, {Gary G.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1634/theoncologist.2012-0051",
language = "English (US)",
volume = "17",
pages = "1171--1179",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "9",

}

TY - JOUR

T1 - Calcium and vitamin d supplementation during androgen deprivation therapy for prostate cancer

T2 - A critical review

AU - Datta, Mridul

AU - Schwartz, Gary G.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Background.Lossofbonemineraldensityisanunintended consequence of androgen deprivation therapy in men with prostate cancer. Supplementation with calcium and/or vitamin D in these men seems logical and is advocated by many lay and professional groups. Methods. We reviewed guidelines for calcium and vitamin D supplementation and the results of clinical trials of calcium and vitamin D supplementation on bone mineral density in men with prostate cancer undergoing androgen deprivation therapy. Results. Whether supplementation of men undergoing androgen deprivation therapy with calcium and/or vitamin D results in higher bone mineral density than no supplementation has not been tested. The results of 12 clinical trials show that, at the doses commonly recommended, 500-1,000 mg calcium and 200-500 IU vitamin D per day, men undergoing androgen deprivation lose bone mineral density. Conclusion. The doses of calcium and vitamin D that have been tested are inadequate to prevent loss of bone mineral density in men undergoing androgen deprivation therapy. In light of evidence that high levels of dietary calcium and calcium supplement use are associated with higher risks for cardiovascular disease and advanced prostate cancer, intervention studies should evaluate the safety as well as the efficacy of calcium and vitamin D supplementation in these men.

AB - Background.Lossofbonemineraldensityisanunintended consequence of androgen deprivation therapy in men with prostate cancer. Supplementation with calcium and/or vitamin D in these men seems logical and is advocated by many lay and professional groups. Methods. We reviewed guidelines for calcium and vitamin D supplementation and the results of clinical trials of calcium and vitamin D supplementation on bone mineral density in men with prostate cancer undergoing androgen deprivation therapy. Results. Whether supplementation of men undergoing androgen deprivation therapy with calcium and/or vitamin D results in higher bone mineral density than no supplementation has not been tested. The results of 12 clinical trials show that, at the doses commonly recommended, 500-1,000 mg calcium and 200-500 IU vitamin D per day, men undergoing androgen deprivation lose bone mineral density. Conclusion. The doses of calcium and vitamin D that have been tested are inadequate to prevent loss of bone mineral density in men undergoing androgen deprivation therapy. In light of evidence that high levels of dietary calcium and calcium supplement use are associated with higher risks for cardiovascular disease and advanced prostate cancer, intervention studies should evaluate the safety as well as the efficacy of calcium and vitamin D supplementation in these men.

KW - Androgen deprivation therapy

KW - Bone mineral density

KW - Calcium

KW - Clinical trials

KW - Prostate cancer

KW - Vitamin d

UR - http://www.scopus.com/inward/record.url?scp=84866530576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866530576&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2012-0051

DO - 10.1634/theoncologist.2012-0051

M3 - Review article

C2 - 22836449

AN - SCOPUS:84866530576

VL - 17

SP - 1171

EP - 1179

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 9

ER -